Editorial
Lipid lowering drugs for patients who continue to smoke?
| The first 150 words of the full text of this article appear below. |
For many of us, the issues raised by the prescription of lipid lowering drugs to patients who continue to smoke are perplexing. In particular there is the concern that the benefits of lowering serum cholesterol may be offset by the harmful effects of nicotine; and that general practitioners and hospital doctors who advise on one aspect of a patient's care to the exclusion of another may somehow be construed as approving, or at least accepting of, the fact that their patient continues to smoke.
Risks of smokingSome smokers still cling to the belief, reinforced by the tobacco
companies, that nicotine is not harmful. A sympathetic but firm
explanation of the risks may therefore be helpful. The study of 35 000
British doctors followed from 1951 to 1991 showed that 50% of habitual
smokers die of diseases that have nothing to do with smoking, 25% of
smokers die of smoking related diseases in
This article has been cited by other articles:
-
Reid, F D A, Cook, D G, Whincup, P H
(2002). Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. Heart
88: 15-19
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
